BRPI1012142A2 - sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato - Google Patents
sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamatoInfo
- Publication number
- BRPI1012142A2 BRPI1012142A2 BRPI1012142A BRPI1012142A BRPI1012142A2 BR PI1012142 A2 BRPI1012142 A2 BR PI1012142A2 BR PI1012142 A BRPI1012142 A BR PI1012142A BR PI1012142 A BRPI1012142 A BR PI1012142A BR PI1012142 A2 BRPI1012142 A2 BR PI1012142A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxycyclopentyl
- inden
- ylamino
- pyrrolo
- pyrimidin
- Prior art date
Links
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
- FIYXUOWXHWJDAM-UHFFFAOYSA-N methyl sulfamate Chemical compound COS(N)(=O)=O FIYXUOWXHWJDAM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21622109P | 2009-05-14 | 2009-05-14 | |
| PCT/US2010/001415 WO2010132110A1 (en) | 2009-05-14 | 2010-05-13 | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012142A2 true BRPI1012142A2 (pt) | 2016-03-29 |
Family
ID=42396430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012142A BRPI1012142A2 (pt) | 2009-05-14 | 2010-05-13 | sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9187482B2 (enExample) |
| EP (2) | EP3091020B1 (enExample) |
| JP (3) | JP2012526808A (enExample) |
| KR (2) | KR20170102381A (enExample) |
| CN (2) | CN102421780A (enExample) |
| AU (1) | AU2010248151B2 (enExample) |
| BR (1) | BRPI1012142A2 (enExample) |
| CA (1) | CA2761256C (enExample) |
| IL (1) | IL216201A (enExample) |
| MX (1) | MX2011012108A (enExample) |
| NZ (2) | NZ621128A (enExample) |
| PE (2) | PE20161222A1 (enExample) |
| PH (1) | PH12015501925A1 (enExample) |
| RU (1) | RU2562245C2 (enExample) |
| SG (2) | SG10201402148SA (enExample) |
| UA (1) | UA108986C2 (enExample) |
| WO (1) | WO2010132110A1 (enExample) |
| ZA (1) | ZA201108347B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| KR101925902B1 (ko) * | 2007-08-02 | 2018-12-06 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ1 활성화 효소 억제제의 합성 방법 |
| NZ621128A (en) | 2009-05-14 | 2015-08-28 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate |
| EP2635287A4 (en) * | 2010-11-05 | 2014-06-04 | Millennium Pharm Inc | NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION |
| EA031067B1 (ru) * | 2011-08-24 | 2018-11-30 | Миллениум Фармасьютикалз, Инк. | ИНГИБИТОРЫ Nedd8-АКТИВИРУЮЩЕГО ФЕРМЕНТА |
| AU2012321106C1 (en) | 2011-11-03 | 2016-11-24 | Takeda Pharmaceutical Company Limited | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent |
| EP3536692B1 (en) | 2012-02-17 | 2021-04-07 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
| CA2880813A1 (en) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | Indole-substituted pyrrolopyrimidinyl inhibitors of uba6 |
| CN104822844B (zh) | 2012-10-01 | 2019-05-07 | 米伦纽姆医药公司 | 预测对抑制剂的反应的生物标记物和方法以及其用途 |
| CN105407973A (zh) | 2013-05-14 | 2016-03-16 | 米伦纽姆医药公司 | Nedd8活化酶抑制剂及化学治疗剂的投与 |
| EP3016934B1 (en) | 2013-07-02 | 2018-01-10 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| EP3517112B1 (en) | 2014-07-01 | 2021-04-07 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| CN106008394B (zh) * | 2016-05-23 | 2018-12-04 | 中国人民解放军第二军医大学 | 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途 |
| EP3684363A4 (en) * | 2017-09-21 | 2021-05-12 | Millennium Pharmaceuticals, Inc. | CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES |
| EP3930720A4 (en) * | 2019-02-26 | 2022-12-28 | Millennium Pharmaceuticals, Inc. | COMPOUNDS USEFUL AS ADJUVANTS |
| KR20210115680A (ko) | 2020-03-16 | 2021-09-27 | 서희강 | 연설용 프롬프터 |
| WO2022112951A1 (en) | 2020-11-25 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622561A (en) | 1969-08-18 | 1971-11-23 | Univ Utah | Nucleoside sugar esters of sulfamic acid and method for preparation of the same |
| US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
| JPS62108897A (ja) | 1985-11-05 | 1987-05-20 | Rikagaku Kenkyusho | アスカマイシン誘導体及びその合成法並びに制癌剤 |
| GB8813148D0 (en) | 1988-06-03 | 1988-07-06 | Glaxo Group Ltd | Chemical compounds |
| GB8826205D0 (en) | 1988-11-09 | 1988-12-14 | Wellcome Found | Heterocyclic compounds |
| US5726302A (en) | 1989-09-15 | 1998-03-10 | Gensia Inc. | Water soluble adenosine kinase inhibitors |
| US5763596A (en) | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
| US5864033A (en) | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| US5470898A (en) | 1993-06-30 | 1995-11-28 | Montell North America Inc. | Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith |
| GB9325809D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
| GB9325810D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
| US6210917B1 (en) | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
| US5767097A (en) | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US5973161A (en) | 1996-03-18 | 1999-10-26 | The University Of North Carolina At Chapel Hill | Enantioselective synthesis of cyclopentenes |
| US5824657A (en) | 1997-03-18 | 1998-10-20 | Cubist Pharmaceuticals, Inc. | Aminoacyl sulfamides for the treatment of hyperproliferative disorders |
| US6734283B1 (en) | 1997-12-19 | 2004-05-11 | Millennium Pharmaceuticals, Inc. | Human proteins responsible for NEDD8 activation and conjugation |
| JPH11228422A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
| JPH11228446A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
| KR20040028657A (ko) | 2000-10-18 | 2004-04-03 | 파마셋, 리미티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| AU2002364536B2 (en) | 2001-12-07 | 2008-10-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
| WO2003106477A1 (en) | 2002-06-01 | 2003-12-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| US7338957B2 (en) | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1680431A1 (en) | 2003-10-17 | 2006-07-19 | Rigel Pharmaceuticals, Inc. | Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors |
| EP1730122A2 (en) | 2004-03-30 | 2006-12-13 | Taisho Pharmaceutical Co., Ltd | Pyrimidine derivatives and methods of treatment related to the use thereof |
| US20050282818A1 (en) | 2004-06-22 | 2005-12-22 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| CA2596424C (en) | 2005-02-04 | 2016-03-29 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| ES2593433T3 (es) * | 2006-02-02 | 2016-12-09 | Millennium Pharmaceuticals, Inc. | Inhibidores de las enzimas activadoras E1 |
| DE602007009998D1 (de) | 2006-08-08 | 2010-12-02 | Millennium Pharm Inc | Heteroarylverbindungen als hemmer der e1-aktivierenden enzyme |
| KR101925902B1 (ko) * | 2007-08-02 | 2018-12-06 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ1 활성화 효소 억제제의 합성 방법 |
| NZ621128A (en) | 2009-05-14 | 2015-08-28 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate |
| AU2012321106C1 (en) | 2011-11-03 | 2016-11-24 | Takeda Pharmaceutical Company Limited | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent |
| CN105407973A (zh) | 2013-05-14 | 2016-03-16 | 米伦纽姆医药公司 | Nedd8活化酶抑制剂及化学治疗剂的投与 |
-
2010
- 2010-05-13 NZ NZ621128A patent/NZ621128A/en not_active IP Right Cessation
- 2010-05-13 MX MX2011012108A patent/MX2011012108A/es not_active Application Discontinuation
- 2010-05-13 SG SG10201402148SA patent/SG10201402148SA/en unknown
- 2010-05-13 RU RU2011150826/04A patent/RU2562245C2/ru not_active IP Right Cessation
- 2010-05-13 CN CN2010800213224A patent/CN102421780A/zh active Pending
- 2010-05-13 SG SG2011081957A patent/SG175929A1/en unknown
- 2010-05-13 KR KR1020177024122A patent/KR20170102381A/ko not_active Ceased
- 2010-05-13 NZ NZ596470A patent/NZ596470A/en not_active IP Right Cessation
- 2010-05-13 EP EP16159438.7A patent/EP3091020B1/en active Active
- 2010-05-13 EP EP10732492A patent/EP2430026A1/en not_active Withdrawn
- 2010-05-13 AU AU2010248151A patent/AU2010248151B2/en not_active Ceased
- 2010-05-13 UA UAA201114830A patent/UA108986C2/uk unknown
- 2010-05-13 BR BRPI1012142A patent/BRPI1012142A2/pt not_active IP Right Cessation
- 2010-05-13 KR KR1020117029162A patent/KR20120024715A/ko not_active Ceased
- 2010-05-13 PE PE2016001604A patent/PE20161222A1/es not_active Application Discontinuation
- 2010-05-13 CN CN201410200959.XA patent/CN104016987A/zh active Pending
- 2010-05-13 JP JP2012510795A patent/JP2012526808A/ja not_active Withdrawn
- 2010-05-13 CA CA2761256A patent/CA2761256C/en not_active Expired - Fee Related
- 2010-05-13 US US12/779,331 patent/US9187482B2/en not_active Expired - Fee Related
- 2010-05-13 PE PE2011001962A patent/PE20120907A1/es not_active Application Discontinuation
- 2010-05-13 WO PCT/US2010/001415 patent/WO2010132110A1/en not_active Ceased
-
2011
- 2011-11-08 IL IL216201A patent/IL216201A/en not_active IP Right Cessation
- 2011-11-14 ZA ZA2011/08347A patent/ZA201108347B/en unknown
-
2015
- 2015-01-16 JP JP2015006444A patent/JP2015096547A/ja not_active Withdrawn
- 2015-09-01 PH PH12015501925A patent/PH12015501925A1/en unknown
- 2015-10-09 US US14/879,151 patent/US10016427B2/en not_active Expired - Fee Related
-
2017
- 2017-02-08 JP JP2017020911A patent/JP2017105816A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012142A2 (pt) | sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato | |
| FIC20253002I1 (fi) | Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola | |
| FIC20240026I1 (fi) | Etrasimodi tai sen farmaseuttisesti hyväksyttävä suola, kuten etrasimodiarginiini | |
| NO2020034I1 (no) | Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid | |
| EP2143024A4 (en) | REQUEST GENERATION USING ENVIRONMENTAL CONFIGURATION | |
| BRPI0906744A2 (pt) | Inserções de amortecimento de espuma | |
| BRPI0916609A2 (pt) | Processo para a preparação de um macrociclo | |
| BRPI0820733A2 (pt) | Processo para a preparação de macrociclo | |
| DE112007000863A5 (de) | Maschinenständer | |
| EP1999793A4 (en) | DYNAMIC ARRAY ARCHITECTURE | |
| DK2384326T3 (da) | Pyrrolo[2,3-d]pyrimidinforbindelser | |
| EP2077901A4 (en) | OKULAR RADIOSURGERY | |
| EP2201484A4 (en) | INTERLANGUE RESEARCH | |
| EP1899867A4 (en) | SYSTEM FOR GENERATING RELATED SEARCH QUESTIONS | |
| DK2170831T3 (da) | Benzazepin-derivater egnede som vasopressin-antagonister | |
| BRPI0920077A2 (pt) | espuma estrutural à base de epóxido com tenacidade melhorada | |
| BRPI0819831A2 (pt) | derivados de amidas de áciodo 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-carboxílico | |
| IL193713A0 (en) | Injector piston nest | |
| EP1985623A4 (en) | PROCESS FOR PRODUCING PROTEOGLYCANS | |
| AT504058A3 (de) | Landmaschine | |
| EP2511276A4 (en) | Pyrrolo [2,3-D] pyrimidine derivative | |
| ITMI20060082A1 (it) | Processo per la preparazione di biodiesel | |
| BRPI0908075A2 (pt) | Antagonísta muscarínicos de pde4-duplos farmacóforos | |
| EP2054181A4 (en) | ASSEMBLY DEVICE FOR INJECTION UNIT | |
| FR2909583B1 (fr) | Machine de thermoformage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |